Skip to main content
. Author manuscript; available in PMC: 2009 Dec 1.
Published in final edited form as: Immunol Rev. 2008 Dec;226:248–262. doi: 10.1111/j.1600-065X.2008.00704.x

Fig. 2. IL-35-deficient Tregs fail to cure inflammatory bowel disease.

Fig. 2

Rag1−/− mice received naive effector T cells via the tail vein. After 3–4 weeks, mice developed clinical symptoms of inflammatory bowel disease and were either untreated or given wildtype or Ebi3−/− (IL-35 deficient) Tregs. Histological sections of representative colons were stained with Alcian blue/PAS (Periodic acid Schiff) (1).